185428-95-9

Basic information

• Product Name: Methyl 1-benzylbenzoiMidazole-5-carboxylate
• Synonyms: Methyl 1-benzylbenzoiMidazole-5-carboxylate
• CAS NO: 185428-95-9
• Molecular Formula: C₁₆H₁₄N₂O₂
• Molecular Weight: 266.29456
• Mol File: 185428-95-9.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Methyl 1-benzylbenzoiMidazole-5-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 1-benzylbenzoiMidazole-5-carboxylate(185428-95-9)
• EPA Substance Registry System: Methyl 1-benzylbenzoiMidazole-5-carboxylate(185428-95-9)

Safety Data

• Hazardous Substances Data: 185428-95-9(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 100-46-9 benzylamine 
• 149-73-5 trimethyl orthoformate 
• 100-39-0 benzyl bromide 
• 26663-77-4 methyl 1H-benzo[d]imidazole-5-carboxylate 
• 329-59-9 4-fluoro-3-nitro-benzoic acid methyl ester 
• 64-18-6 formic acid 
• 68502-22-7 3-amino-4-benzylamine-benzoic acid methyl ester 
• 122-51-0 orthoformic acid triethyl ester 
• 453-71-4 3-nitro-4-fluorobenzoic acid 
• 68502-46-5 4-benzylamine-3-nitro-benzoic acid methyl ester 

Downstream Products

• 185428-96-0 (1-benzyl-1H-benzimidazole-5-yl)methanol 

Relevant articles and documents

Discovery of a Potent FLT3 Inhibitor (LT-850-166) with the Capacity of Overcoming a Variety of FLT3 Mutations

Secondary mutations of FLT3 have become the main mechanism of FLT3 inhibitor resistance that presents a significant clinical challenge. Herein, a series of pyrazole-3-amine derivatives were synthesized and optimized to overcome the common secondary resistance mutations of FLT3. The structure-activity relationship and molecular dynamics simulation studies illustrated that the ribose region of FLT3 could be occupied to help address the obstacle of secondary mutations. Among those derivatives, compound 67 exhibited potent and selective inhibitory activities against FLT3-ITD-positive acute myeloid leukemia (AML) cells and possessed equivalent potency against transformed BaF3 cells with a variety of secondary mutations. Besides, cellular mechanism assays demonstrated that 67 strongly inhibited phosphorylation of FLT3 and its downstream signaling factors, as well as induced cell cycle arrest and apoptosis in MV4-11 cells. In the MV4-11 xenograft models, 67 exhibited potent antitumor potency without obvious toxicity. Taken together, these results demonstrated that 67 might be a drug candidate for the treatment of FLT3-ITD-positive AML.

Cu-Catalyzed Regioselective C-H Alkylation of Benzimidazoles with Aromatic Alkenes

Herein we report a novel Cu-catalyzed regioselective C2-H alkylation of benzimidazoles with aromatic alkenes. The reaction features exclusive regioselectivity and broad substrate scope in the intermolecular alkylation of benzimidazoles with terminal and i

GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT

The present invention relates to a novel compound having GPR40 receptor agonist activity that promotes insulin secretion and inhibits blood sugar rise after glucose loading, and is thereby useful for the treatment of diabetes and complications thereof, the preparation method thereof and pharmaceutical composition containing them as an active ingredient.

Soluble polymer-supported synthesis of a benzimidazole library

The synthesis of benzimidazole 1 using a liquid phase approach is described. Aromatic substitution of immobilized o-fluoronitrobenzene 2 with various amines to o-nitroaniline derivatives 3 is carried out in methylene chloride. Reduction of the aromatic nitro group, followed by subsequent cyclization/elimination gives the benzimidazole skeleton. The crude library members obtained are of high yields and chemical purities after cleavage.

Benzimidazole derivatives, their preparation and their therapeutic use

Compounds of formula (I): STR1 [wherein: X represents an optionally substituted benzimidazole group; Y represents an oxygen or sulfur atom; Z represents a 2,4-dioxothiazolidin-5-ylidenylmethyl, 2,4-dioxothiazolidin-5-ylmethyl, 2,4-dioxooxazolidin-5-ylmethyl, 3,5-dioxooxadiazolidin-2-ylmethyl or N-hydroxyureidomethlyl group; R represents hydrogen, alkyl, alkoxy, halogen, hydroxy, nitro, amino or aralkyl; and m is an integer from 1 to 5]; have valuable activity for the treatment and/or prophylaxis of a variety of disorders, including one or more of: hyperlipemia, hyperglycemia, obesity, impaired glucose tolerance (IGT), insulin resistance and diabetic complications.

Benzimidazole derivatives, their preparation and their therapeutic use

Compounds of formula (I): [in which: X represents an optionally substituted benzimidazole group; Y represents an oxygen or sulphur atom; Z represents a 2,4-dioxothiazolidin-5-ylidenylmethyl, 2,4-dioxothiazolidin-5-ylmethyl, 2,4-dioxo-oxazolidin-5-ylmethyl, 3,5-dioxooxadiazolidin-2-ylmethyl or N-hydroxyureidomethyl group; R represents hydrogen, alkyl, alkoxy, halogen, hydroxy, nitro, amino or aralkyl; and mis an integer from 1 to 5]; have valuable activity for the treatment and/or prophylaxis of a variety of disorders, including one or more of: hyperlipemia, hyperglycemia, obesity, impaired glucose tolerance (IGT), insulin resistance and diabetic complications.